Literature DB >> 21570976

The BRCA1 ubiquitin ligase and homologous recombination repair.

Tomohiko Ohta1, Ko Sato, Wenwen Wu.   

Abstract

Impairment of homologous recombination (HR), a vital process employed during repair of DNA double strand breaks and stalled DNA replication, provides a valuable opportunity for the cell to become transformed. Once transformed, the impairment turns to be a target for therapy as exemplified by the synthetic lethal strategy such as poly (ADP-ribose) polymerase (PARP) inhibitor for BRCA1/2-defective breast and ovarian cancer. Hence, improving mechanistic understanding of HR has emerged as an urgent issue to address due to the high clinical demand. Ubiquitin modification plays a central role in HR and more than a few E3 ubiquitin ligases have been implicated in the process. However, the significance of the activity of one such key E3 ligase, BRCA1, has not yet been clarified and remains as a major obstacle in the field. Here, we review recent advances in our understanding of BRCA1 function in HR and discuss possible roles of the activity.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570976     DOI: 10.1016/j.febslet.2011.05.005

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

1.  A BRCA1-interacting lncRNA regulates homologous recombination.

Authors:  Vivek Sharma; Simran Khurana; Nard Kubben; Kotb Abdelmohsen; Philipp Oberdoerffer; Myriam Gorospe; Tom Misteli
Journal:  EMBO Rep       Date:  2015-09-27       Impact factor: 8.807

2.  K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death.

Authors:  Jinho Seo; Eun-Woo Lee; Jihye Shin; Daehyeon Seong; Young Woo Nam; Manhyung Jeong; Seon-Hyeong Lee; Cheolju Lee; Jaewhan Song
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

Review 3.  Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC).

Authors:  Jia Wei; Teresa Moran; Zhengyun Zou; Xiaoping Qian; Lifeng Wang; Carlos Camps; Wenjing Hu; Imane Chaib; Belén Sanchez; Lixia Xu; Niki Karachaliou; María Sanchez-Ronco; Baorui Liu; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

4.  Dissenting degradation: Deubiquitinases in cell cycle and cancer.

Authors:  Thomas Bonacci; Michael J Emanuele
Journal:  Semin Cancer Biol       Date:  2020-03-20       Impact factor: 15.707

Review 5.  BRCA1 and microRNAs: emerging networks and potential therapeutic targets.

Authors:  Suhwan Chang; Shyam K Sharan
Journal:  Mol Cells       Date:  2012-07-24       Impact factor: 5.034

6.  Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.

Authors:  Brent J Guppy; Kirk J McManus
Journal:  Cell Oncol (Dordr)       Date:  2017-05-01       Impact factor: 6.730

7.  DNA damage and breast cancer.

Authors:  Jennifer D Davis; Shiaw-Yih Lin
Journal:  World J Clin Oncol       Date:  2011-09-10

8.  The Histone Variant MacroH2A1 Is a BRCA1 Ubiquitin Ligase Substrate.

Authors:  Beom-Jun Kim; Doug W Chan; Sung Yun Jung; Yue Chen; Jun Qin; Yi Wang
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

9.  BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation.

Authors:  S Shabbeer; D Omer; D Berneman; O Weitzman; A Alpaugh; A Pietraszkiewicz; S Metsuyanim; A Shainskaya; M Z Papa; R I Yarden
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

10.  Pathway choice in DNA double strand break repair: observations of a balancing act.

Authors:  Inger Brandsma; Dik C Gent
Journal:  Genome Integr       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.